Log in to save to my catalogue

Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS

Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_DiVA_org_umu_175822

Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

In a phase 1–2 dose-escalation trial involving adults with ALS due to
SOD1
mutations who received intrathecal tofersen (an antisense oligonucleotide) or placebo, the levels of mutant SOD1 in the CSF were 33 percentage points lower in the highest-dose tofersen group than in the placebo group.

Alternative Titles

Full title

Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_swepub_primary_oai_DiVA_org_umu_175822

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_DiVA_org_umu_175822

Other Identifiers

ISSN

0028-4793,1533-4406

E-ISSN

1533-4406

DOI

10.1056/NEJMoa2003715

How to access this item